Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

How Future Surgery Will Benefit From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Related Measures Perspective From Italian Young Surgeon Society (SPIGC)

NCT05323851 is registered in ClinicalTrials.gov with University of Rome Tor Vergata as lead sponsor.

NCT NCT05323851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05323851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
How Future Surgery Will Benefit From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Related Measures Perspective From Italian Young Surgeon Society (SPIGC)
Lead sponsor
University of Rome Tor Vergata
Phase
Observational
Overall status
Completed
Start date
March 16, 2022
Completion date
July 1, 2022
Enrollment
581 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, health behavior